MAPKAPMitogen Activated Protein Kinase Activated Protein Kinase
References in periodicals archive ?
Moerae Matrix is a privately-held, clinical-stage company focused on the discovery and development of inhibitors of MAPKAP Kinase 2 to treat fibrotic and inflammatory diseases.
Based on proprietary technology from Purdue University, the company is advancing a suite of peptide therapeutics that target MAPKAP kinase 2 (MK2), a key terminal kinase in the TGF-beta/p38 pathway, with a high degree of specificity.
As a leader and widely-respected peer in the pulmonary community based on his pioneering development work in Idiopathic Pulmonary Fibrosis, Bill will be a valuable addition to the Moerae team as we move our platform of MAPKAP Kinase 2 inhibitors forward," said Cynthia Lander, PhD, Moerae's Chief Executive Officer.